PubMed Health⌕ Search

Biomedical subjects

S S Stefani

Publications and source records attributed to S S Stefani.

23 records · Page 2Linked to original sources

Inhibition by ionophore A23187 of the cytotoxicity of vincristine, colchicine and X-rays to leukemic lymphocytes.

The ionophore A23187 was tested for its effect on the sensitivity of normal and leukemic lymphocytes to colchicine, vincristine, and X-irradiation. The ionophore was used because it transfers divalent cations through biological membranes and causes the transformation of normal lymphocytes. The sensitivity of the cells was measured by incubation of lymphocyte suspensions with and without reagent at 37 degrees C for one to seven days and counting the number of viable lymphocytes before and after incubation. Viability of the cells was judged by cytologic criteria as visualized by phase contrast microscopy. Lymphocytes were obtained from patients with chronic lymphocytic leukemia and from normal persons. Colchicine and vincristine killed in one day non-dividing leukemic lymphocytes while normal lymphocytes were much less sensitive to the two alkaloids. X-irradiation (1000 rad) killed nearly all leukemic lymphocytes in two days and normal lymphocytes in three days. Ionophore A23187 (2 X 10(-5)M) was moderately toxic to normal but not to leukemic lymphocytes and caused the transformation of both types of cells. The ionophore inhibited the cytocidal action of colchicine and vincristine to leukemic but not to normal lymphocytes and inhibited the action of X-irradiation to both types of lymphocytes. The present findings and a review of the literature suggest the hypothesis that calcium or other divalent ions are involved in the cytotoxicity of colchicine, vincristine, and X-irradiation of leukemic lymphocytes and that there may be an abnormality of the metabolism of divalent ions in leukemic lymphocytes.

Anti-Bacterial Agents↗

Active T-rosette-forming cells in the peripheral blood of cancer patients.

We studied a subpopulation of the thymus-dependent rosette-forming lymphocytes from the peripheral blood of normal individuals and of untreated patients with solid tumors or hematological cancers. This subpopulation of the thymus-dependent rosette-forming cells (T-RFC), termed the "active T-RFC," may be relatively more immunocompetent than the total thymus-dependent population. The mean percentages and absolute numbers of active T-RFC of 40 healthy adult controls were 25.8 +/- 4.3 and 626 +/- 213, respectively. There was no difference in the percentage of active T-RFC between the controls (smokers and nonsmokers) and the 102 untreated patients with solid (localized or metastasized) tumors, 4 patients with Hodgkin's disease, or the 10 patients with non-Hodgkin's lymphomas. However, the absolute number of active T-RFC was significantly less in the cancer patients than in the controls. Eight patients with chronic lymphocytic leukemia had lower percentages but higher absolute numbers of active T-RFC, whereas 6 patients with multiple myeloma had higher percentage and lower absolute numbers than the controls. Following radiation therapy, 61 patients with solid tumors showed no difference in the percentage of active T-RFC, but the corresponding absolute numbers declined significantly. A good correlation was seen with patients having positive microbial skin test responses and normal percentage of active T-RFC. The significance of both the percentages and absolute numbers of active T-RFC and their relationship to patient status are discussed.

Adult↗